BDX

Becton, Dickinson and Company (BDX) | Rumor.io

Becton, Dickinson

BDX

Attention (50-day avg)0%

Attention rank (50-day avg)#2,255

Bullish sentiment (50-day avg)86%

Price to earnings ratio31.9

Market capitalization50.1B

Earnings per share5.77

Dividend yield (TTM)2.28%

Revenue (annual)21.8B

Net income (annual)1.7B

Social

What share of all stock conversation is about BDX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 23

Hospital inventory levels have normalized, with disposable single-use medical equipment orders slowing down, potentially benefiting Becton, Dickinson and Company (BDX).
The demand for wildfire smoke filtration products has increased, driving up industrial stock prices, which may have a positive impact on BDX.
Becton, Dickinson and Company (BDX) may benefit from the normalization of hospital inventories, the end of one-time bulk orders for disposable medical supplies, and the growing demand for post-consumer recycled plastic resin.

Generated by AI

Sentiment

Of the messages about BDX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	89.84% +0.4
Bearish	—	—	—	10.16% -0.4

Bullish· Mar 1

Becton Dickinson and Company (BDX) has outperformed the Dow Jones with a 15.7% YTD return.
BDX has exceeded expected quarterly EPS in 3 months, despite concerns over Chinese demand and vaccine needs.
In 3 months, BDX outperformed the NY Dow, showing strong market momentum.

Bearish· Sep 23

Citi downgraded Becton Dickinson to Sell from Neutral, citing lower growth expectations.
The target price for Becton Dickinson was reduced to $165 from $167.
Citi analyst Amit Hazan expects Becton Dickinson to decline, assigning a Sell rating and a lower target price.

Generated by AI

Topics

Of the messages about BDX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	0%	42.92%
Earnings	—	—	33.33%	19.11%
Controversies	—	—	0%	1.07%
Technical Analysis	—	—	0%	24.79%
Analysts	—	—	33.33%	5.6%
Macro	—	—	33.33%	6.51%

Earnings· Feb 9

Becton Dickinson and Company's Q1 2026 earnings report showed adjusted EPS of $2.91, beating estimates of $2.81, and revenue of $5.25B, beating estimates of $5.15B.
The company provided FY2026 guidance, with adjusted EPS expected to be $12.35-$12.65 and revenue growth expected to be in the low single-digit range.
Becton Dickinson's Q1 2026 earnings report showed a decline in earnings per share compared to the same quarter last year, with a 17% decline in EPS and a 1.6% increase in revenue.

Analysts· Feb 7

Becton Dickinson and Company (BDX) has been downgraded by several analysts, including KeyCorp, Cowen & Co, and Raymond James.
Price targets for BDX have been adjusted downward by analysts at Wells Fargo & Co, Morgan Stanley, and Raymond James.
BDX's "Outperform" rating has been reaffirmed by Cowen & Co, while Raymond James downgraded its rating to "Outperform".

Announcements· Feb 10

Becton, Dickinson and Company (BDX) reported Q1 FY2026 results with revenue of $5.3 billion, up 0.4%, driven by double-digit growth in key areas.
BDX's Life Sciences spinoff to Waters closed, slashing reported earnings base and causing a 18.91% decline in the stock price.
BDX announced tender offers for outstanding debt securities, providing an update on the company's financial management and capital structure.

Macro· Sep 7

Global stocks are declining ahead of the US decision to impose further tariffs on USD$200bn in Chinese goods.
The US Large-Cap Global Top Picks report has rated Becton-Dickinson (BDX) as 'Unattractive'.
Becton-Dickinson's sale of its Advanced Bioprocessing unit to Thermo Fischer will result in a tax gain for the company.

Generated by AI

Community

Of the messages about BDX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	25.05%
Newcomers	—	—	100%	74.95%

Regulars· Feb 9

Becton Dickinson reported Q1 FY26 results with adj. EPS of $2.91 and revenue of $5.252B, a 1.63% YoY increase.
The company completed its biosciences spin-off and combination with Waters Corporation, resulting in a $4B cash gain and Waters stake.
BD's Q1 FY26 earnings guidance was cut to $12.35-$12.65, from a previously estimated $14.72, while FY2026 adj. EPS guidance was reduced.

Newcomers· Jul 23

Becton, Dickinson and Company's hospital inventory levels have normalized after one-time bulk orders for disposable medical supplies ended.
The company's disposable single-use medical equipment orders have slowed down, and hospital inventories are now balanced.
The company's stock has been affected by shifting cross-Asian export policy news headlines, creating uncertainty for the rare earth magnet supply chain.

Generated by AI

News

Becton Dickinson & Co. stock outperforms competitors on strong trading day

4d agoMarketWatch

Becton Dickinson & Co. stock underperforms Thursday when compared to competitors

5d agomarketwatch.com

Becton Dickinson & Co. stock underperforms Tuesday when compared to competitors despite daily gains

7d agoMarketWatch

Becton, Dickinson Names Arthur Hu Chief Information, Digital Officer

Becton, Dickinson (BDX) has appointed Arthur Hu chief information and digital officer, starting Sept

8d agoYahoo Finance

Why Is Becton Dickinson (BDX) Facing Fresh SEC And Litigation Pressure?

Becton Dickinson (NYSE:BDX) reached an SEC cease and desist settlement over past Alaris infusion pump risk disclosures, including a civil penalty and creation of a Fair Fund for investors. Subsidiary C.R. Bard recently faced a plaintiff verdict in Bard PowerPort litigation, with thousands of related product liability cases still pending. The Alaris disclosure settlement and Bard PowerPort verdict both tie into a wider pattern of legal and compliance pressures our research tracks. We have...

10d agoYahoo Finance

Becton Dickinson & Co. stock underperforms Wednesday when compared to competitors

13d agoMarketWatch

Also Discussed

Investors talking about BDX also mention

#	Name	Attention
1	Stryker CorporationSYK	0.01%+0.01
2	AXDX - Accelerate Diagnostics, Inc.	——
3	Qiagen N.V.QGEN	0%+0
4	QuidelOrtho CorporationQDEL	0%new
5	Aflac IncorporatedAFL	0%0
6	Parker-Hannifin CorporationPH	0%0
7	Labcorp Holdings Inc.LH	0%0
8	Thermo Fisher Scientific Inc.TMO	0%0
9	Abbott LaboratoriesABT	0%-0.03
10	SempraSRE	0%0

Becton, Dickinson and Company

Healthcare
Medical Instruments & Supplies

Becton, Dickinson and Company is a global medical technology company that develops, manufactures, and sells a broad range of products used across healthcare and life sciences. Becton, Dickinson and Company serves hospitals, physicians, clinical laboratories, researchers, and public health organizations with medical supplies, diagnostic systems, laboratory equipment, and interventional devices. Its current business centers on medical essentials, connected care, biopharma systems, and interventional products, supporting workflows such as specimen handling, medication delivery, infection prevention, vascular access, and surgical procedures. The company’s portfolio also includes tools and technologies used in drug delivery, patient safety, and clinical research. Headquartered in Franklin Lakes, New Jersey, Becton, Dickinson and Company plays an important role in enabling medical discovery, improving care delivery, and supporting routine operations in healthcare settings worldwide.

Website

Location

1 Becton Drive

Franklin Lakes, NJ, 07417-1880

United States

Social

What share of all stock conversation is about BDX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 23

Hospital inventory levels have normalized, with disposable single-use medical equipment orders slowing down, potentially benefiting Becton, Dickinson and Company (BDX).
The demand for wildfire smoke filtration products has increased, driving up industrial stock prices, which may have a positive impact on BDX.
Becton, Dickinson and Company (BDX) may benefit from the normalization of hospital inventories, the end of one-time bulk orders for disposable medical supplies, and the growing demand for post-consumer recycled plastic resin.

Generated by AI

Sentiment

Of the messages about BDX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	89.84% +0.4
Bearish	—	—	—	10.16% -0.4

Bullish· Mar 1

Becton Dickinson and Company (BDX) has outperformed the Dow Jones with a 15.7% YTD return.
BDX has exceeded expected quarterly EPS in 3 months, despite concerns over Chinese demand and vaccine needs.
In 3 months, BDX outperformed the NY Dow, showing strong market momentum.

Bearish· Sep 23

Citi downgraded Becton Dickinson to Sell from Neutral, citing lower growth expectations.
The target price for Becton Dickinson was reduced to $165 from $167.
Citi analyst Amit Hazan expects Becton Dickinson to decline, assigning a Sell rating and a lower target price.

Generated by AI

Topics

Of the messages about BDX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	0%	42.92%
Earnings	—	—	33.33%	19.11%
Controversies	—	—	0%	1.07%
Technical Analysis	—	—	0%	24.79%
Analysts	—	—	33.33%	5.6%
Macro	—	—	33.33%	6.51%

Earnings· Feb 9

Becton Dickinson and Company's Q1 2026 earnings report showed adjusted EPS of $2.91, beating estimates of $2.81, and revenue of $5.25B, beating estimates of $5.15B.
The company provided FY2026 guidance, with adjusted EPS expected to be $12.35-$12.65 and revenue growth expected to be in the low single-digit range.
Becton Dickinson's Q1 2026 earnings report showed a decline in earnings per share compared to the same quarter last year, with a 17% decline in EPS and a 1.6% increase in revenue.

Analysts· Feb 7

Becton Dickinson and Company (BDX) has been downgraded by several analysts, including KeyCorp, Cowen & Co, and Raymond James.
Price targets for BDX have been adjusted downward by analysts at Wells Fargo & Co, Morgan Stanley, and Raymond James.
BDX's "Outperform" rating has been reaffirmed by Cowen & Co, while Raymond James downgraded its rating to "Outperform".

Announcements· Feb 10

Becton, Dickinson and Company (BDX) reported Q1 FY2026 results with revenue of $5.3 billion, up 0.4%, driven by double-digit growth in key areas.
BDX's Life Sciences spinoff to Waters closed, slashing reported earnings base and causing a 18.91% decline in the stock price.
BDX announced tender offers for outstanding debt securities, providing an update on the company's financial management and capital structure.

Macro· Sep 7

Global stocks are declining ahead of the US decision to impose further tariffs on USD$200bn in Chinese goods.
The US Large-Cap Global Top Picks report has rated Becton-Dickinson (BDX) as 'Unattractive'.
Becton-Dickinson's sale of its Advanced Bioprocessing unit to Thermo Fischer will result in a tax gain for the company.

Generated by AI

Community

Of the messages about BDX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	25.05%
Newcomers	—	—	100%	74.95%

Regulars· Feb 9

Becton Dickinson reported Q1 FY26 results with adj. EPS of $2.91 and revenue of $5.252B, a 1.63% YoY increase.
The company completed its biosciences spin-off and combination with Waters Corporation, resulting in a $4B cash gain and Waters stake.
BD's Q1 FY26 earnings guidance was cut to $12.35-$12.65, from a previously estimated $14.72, while FY2026 adj. EPS guidance was reduced.

Newcomers· Jul 23

Becton, Dickinson and Company's hospital inventory levels have normalized after one-time bulk orders for disposable medical supplies ended.
The company's disposable single-use medical equipment orders have slowed down, and hospital inventories are now balanced.
The company's stock has been affected by shifting cross-Asian export policy news headlines, creating uncertainty for the rare earth magnet supply chain.

Generated by AI

Becton, Dickinson

Social

Jul 23

Bullish· Mar 1

Bearish· Sep 23

Earnings· Feb 9

Analysts· Feb 7

Announcements· Feb 10

Macro· Sep 7

Regulars· Feb 9

Newcomers· Jul 23

Becton Dickinson & Co. stock outperforms competitors on strong trading day

Becton Dickinson & Co. stock underperforms Thursday when compared to competitors

Becton Dickinson & Co. stock underperforms Tuesday when compared to competitors despite daily gains

Becton, Dickinson Names Arthur Hu Chief Information, Digital Officer

Why Is Becton Dickinson (BDX) Facing Fresh SEC And Litigation Pressure?

Becton Dickinson & Co. stock underperforms Wednesday when compared to competitors

Also Discussed

Becton, Dickinson and Company

Company Information

Location

Becton Dickinson & Co. stock outperforms competitors on strong trading day

Becton Dickinson & Co. stock underperforms Thursday when compared to competitors

Becton Dickinson & Co. stock underperforms Tuesday when compared to competitors despite daily gains

Becton, Dickinson Names Arthur Hu Chief Information, Digital Officer

Why Is Becton Dickinson (BDX) Facing Fresh SEC And Litigation Pressure?

Becton Dickinson & Co. stock underperforms Wednesday when compared to competitors

Also Discussed

Social

Jul 23

Bullish· Mar 1

Bearish· Sep 23

Earnings· Feb 9

Analysts· Feb 7

Announcements· Feb 10

Macro· Sep 7

Regulars· Feb 9

Newcomers· Jul 23